Key facts
- This page summarizes Joshua M. Eizen's Form 4 filing for AN2 Therapeutics, Inc. (ANTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 06 Nov 2026, 18:20.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Additional SEC filing notes
Footnote F1
Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on November 4, 2026.
Footnote F2
Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date.
Footnote F3
Reflects the adjusted total which includes the purchase of 3,818 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2026.
SEC remarks
Chief Operating Officer and Chief Legal Officer